Tag: peptide receptor radionuclide therapy

PRRT infographic, segment_2

Peptide Receptor Radionuclide Therapy, PRRT: Updates and Locations

July 26, 2018

Since we shared the news of the FDA’s January 26, 2018 approval of peptide receptor radionuclide therapy, PRRT, with Lutathera  (lutetium Lu 177 dotatate), more information has become available for the neuroendocrine tumor community, including…

READ MORE
FDA approval_3

PRRT – FDA Approves Lutathera®, What’s Next?

February 20, 2018

The FDA approval of Lutathera®, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018 signals a new era in treatment options for the neuroendocrine cancer community.  It has also raised a host of questions including:

  • What exactly is
READ MORE
Lu-177

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

May 3, 2016

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017.  Additionally, an

READ MORE
Diane Reidy Lagunes, MD, Memorial Sloan Kettering_2

News and Notes for the Carcinoid and Neuroendocrine Tumor Community, March 2016

March 23, 2016

Breaking News from Advanced Accelerator Applications (AAA) about PRRT Treatment— Advanced Accelerator Applications announced on March 23 that the company has initiated an expanded access program (EAP) in the United States for the investigational…

READ MORE
Jonathan Strosberg on NETTER-1

Neuroendocrine Tumors to Be Focus of Presentations and Posters at ASCO Gastrointestinal Cancers Symposium

January 14, 2016

Presentations on recent advances in the treatment of neuroendocrine tumors (NETs) and new findings from the NETTER-1 clinical study on PRRT with Lutathera along with posters on a wide variety of subjects about NETs will be part of the program during the…

READ MORE
Jennifer Chan, MD and Matthew Kulke, MD

Neuroendocrine Tumors Focus of Upcoming Issue of Hematology/Oncology Clinics

November 27, 2015

Neuroendocrine Tumors will be featured in the February 2016 issue of Hematology/Oncology Clinics. Dr. Jennifer Chan and Dr. Matthew Kulke, both from Dana-Farber Cancer Institute in Boston, Massachusetts are Editors of the issue, published by Elsevier.…

READ MORE
sticky-example

10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

June 12, 2015
  • PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society
READ MORE
Michael Farris Golden Rule

DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment

June 8, 2015

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…

READ MORE
Theranostics 3rd World Congress

3rd Theranostics World Congress Offers Free Patient Program on March 14

February 27, 2015

Johns Hopkins University in Baltimore, Maryland will be the site of the 3rd Theranostics World Congress on Ga-68 & PRRT from March 12-14, 2015. Co-sponsored by the Society of Nuclear Medicine and Molecular Imaging and Johns Hopkins Medicine, the…

READ MORE
Josh Mailman_5

Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging 2014 Meeting

April 25, 2014

Josh Mailman, President of the NorCal CarciNET Community  and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June…

READ MORE